Company / FCF Margin
BioXcel Therapeutics, Inc. FCF Margin History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest FCF Margin
-8974.3%
FY2025
5-year range
-36128.0% / -8974.3%
FY2022-FY2025
Trend
+20.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from -36128.0% to -8974.3% over the past 2 years.
Based on SEC 10-K filings.
-8974.3% in FY2025 with a 3-year CAGR of +13051.8%.
Improved from -36128.0% to -8974.3% over the past 2 years.
FCF Margin over time
Growth rates
- 3-Year Change
- +13051.8pp
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, fcf margin increased 20.1% year-over-year.
Company context
Key Data Points
- Altman Z-Score -17.49 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | FCF MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -8974.3% | +20.1% |
| FY2024 | -11233.8% | +68.9% |
| FY2023 | -36128.0% | -64.0% |
| FY2022 | -22026.1% | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026